Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2011 Mar;39(2):163-70.
doi: 10.1515/jpm.2010.139. Epub 2010 Dec 13.

Birth defects among a cohort of infants born to HIV-infected women on antiretroviral medication

Affiliations
Clinical Trial

Birth defects among a cohort of infants born to HIV-infected women on antiretroviral medication

D Heather Watts et al. J Perinat Med. 2011 Mar.

Abstract

Objective: To determine rate of and risk factors for birth defects in infants born to HIV-infected women receiving nucleoside and protease inhibitor antiretroviral (ARV) therapy.

Methods: Birth defects were evaluated among infants on the Pediatric AIDS Clinical Trials Group 316 trial that studied addition of peripartum nevirapine to established ARV regimen for prevention of mother-to-child transmission. Maternal therapy was categorized by trimester of earliest exposure. Birth defects were coded using conventions of the Antiretroviral Pregnancy Registry.

Results: Birth defects were detected in 60/1414 (4.2%; 95% CI 3.3-5.4%) infants including 30/636 (4.7%; 95% CI 3.2-6.7%) with first trimester ARV exposure and 30/778 (3.9%; 95% CI 2.6-5.5%) with exposure only after the first trimester (P=0.51). Rates of classes of defects were similar between first trimester compared to later exposure groups except heart defects which occurred in 16 (2.5%; 95% CI 1.4-4.1%) with first trimester ARV exposure and in six (0.8%; 95% CI 0.3-1.7%) infants with later exposure (P=0.02). Exposure to ARV was not associated with specific types of heart defects. Two cases of cardiomyopathy were noted.

Conclusion: ARV use in early pregnancy was not associated with an increased risk of birth defects overall. The possible association of ARV exposure with heart defects requires further surveillance.

PubMed Disclaimer

References

    1. Bishop JB, Tani Y, Witt K, Johnson JA, Peddada S, Dunnick J, et al. Mitochondrial damage revealed by morphometric and semiquantitative analysis of mouse pup cardiomyocytes following in utero and postnatal exposure to zidovudine and lamivudine. Toxicol Sci. 2004;81:512–7. - PubMed
    1. Botto LD, Correa A, Erickson JD. Racial and temporal variations in the prevalence of heart defects. Pediatrics. 2001;107:e32–40. - PubMed
    1. Boyd PA, DeVigan C, Khoshnood B, Loane M, Garne E, Dolk H, the EUROCAT working group Survey of prenatal screening policies in Europe for structural malformations and chromosome anomalies, and their impact on detection and termination rates for neural tube defects and Down’s syndrome. Br J Obstet Gynaecol. 2008;115:689–96. - PMC - PubMed
    1. Centers for Disease Control and Prevention Metropolitan Atlanta Congenital Defects Program. Birth defects and genetic diseases branch 6-digit code for reportable congenital anomalies. Revised 08/07. Available at http://www.cdc.gov/ncbddd/bd/documents/MACDPcode%200807.pdf.
    1. Culnane M, Fowler MG, Lee SS, McSherry G, Brady M, O’Donnell K, et al. Lack of long-term effects of in utero exposure to zidovudine among uninfected children born to HIV-infected women. J Am Med Assoc. 1999;281:151–7. - PubMed

Publication types

MeSH terms